罗氏停止开发satralizumab用于DMD骨健康治疗——肌肉萎缩症新闻
Roche halts development of satralizumab for DMD bone health - Muscular Dystrophy News
生命科学资讯
生物技术与制药领域的最新动态
下一代测序市场竞争格局报告2025：聚焦顶尖企业——赛默飞世尔科技、太平洋生物科学、Illumina、罗氏——雅虎财经新加坡
Next Generation Sequencing Market Competitive Landscape Report 2025 Featuring Top Players - Thermo Fisher Scientific, Pacific Biosciences, Illumina, Roche - Yahoo Finance Singapore
罗氏将停止针对杜氏肌营养不良症的骨骼健康治疗研究。
Roche to stop work on bone health treatment for Duchenne
罗氏将停止针对杜氏肌营养不良症的骨健康治疗研究——终点新闻
Roche to stop work on bone health treatment for Duchenne - Endpoints News
罗氏获FDA乳腺癌新药审批日期，备受关注。
Roche gets FDA decision date on closely watched breast cancer drug
罗氏任命澳大利亚肿瘤学家领导早期研究——机遇与挑战并存
Chutes & Ladders—Roche taps Aussie oncologist to lead early research
罗氏任命澳大利亚肿瘤学家领导研究——职业阶梯与滑梯 - 激烈生物科技
Roche taps Aussie oncologist to lead research—Chutes & Ladders - Fierce Biotech
临床试验 - 罗氏
Clinical Trials - Roche
昼夜节律调节器驱动质子电化学梯度优化拟南芥细胞类型特异性生长
A circadian rheostat drives proton electrochemical gradients to optimize cell-type-specific growth in Arabidopsis
罗氏将停止关键抗生素生产，欧盟仿制药困境加剧
Roche to end manufacturing of key antibiotic amid EU’s generic woes - Euractiv
Paragon新生物技术公司Korsana挑战阿尔茨海默病，与罗氏一较高下。
Paragon's new biotech Korsana tackles Alzheimer's like Roche
Paragon最新生物技术将尝试像罗氏一样延缓阿尔茨海默病进程——Endpoints新闻
Paragon's latest biotech will try to slow Alzheimer's like Roche - Endpoints News
Ngs 肿瘤学市场即将迎来繁荣 | Illumina • Roche • Thermo Fisher Scientific - openPR.com
Ngs Oncology Market Is Going to Boom | Illumina • Roche • Thermo Fisher Scientific - openPR.com
罗氏集团员工数量：2007年至2025年 - Statista
Number of Roche Group employees from 2007 to 2025 - Statista
礼来再次押注中国市场；罗氏展示多发性硬化症数据
Lilly bets again on China drugs; Roche showcases MS data
#ACTRIMS26：罗氏多发性硬化症药物芬布替尼优于奥瑞珠单抗，降低残疾进展风险12%
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
罗氏芬尼布替尼在多发性硬化症治疗中展现十年首次突破——欧洲药品评论
Roche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis - European Pharmaceutical Review
罗氏公布BTK抑制剂在Ocrevus试验中三期多发性硬化症成功的数据——Fierce Biotech
Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial - Fierce Biotech
新披露显示，罗氏基因泰克去年裁员至少489人。
Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals
新文件披露：基因泰克去年裁员至少489人——来自《激烈生物科技》
Genentech cut at least 489 jobs last year, new filing reveals - Fierce Biotech